Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis.
Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A. · 2021
Read Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. by Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8008284.txt.
Introduction
Petrelli and co-authors pool evidence on obesity and survival in people with cancer. Their systematic review and meta-analysis covers 203 studies with more than 6.3 million participants. The question was whether obesity predicts better or worse outcomes after a cancer diagnosis. Earlier reports had hinted at an obesity paradox in some diseases.
The authors report that obesity raised overall and cancer-specific mortality overall. The harm was clearest in breast, colon, and uterine cancers. Yet the pattern reversed for a few cancers. Patients with obesity and renal cell carcinoma, lung cancer, or melanoma survived better than leaner patients. The results split a broad question by cancer type.
Catalog record
| CREATOR | Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Association of Obesity With Survival Outcomes in Patients With Cancer By Fausto Petrelli, Alessio Cortellini, Alice Indini, Gianluca Tomasello, Michele Ghidini, Olga Nigro, Massimiliano Salati, Lorenzo Dottorini, Alessandro Iaculli, Antonio Varricchio, Valentina Rampulla, Sandro Barni Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2021.3520 ABSTRACT Key Points Question Is obesity associated with better prognosis in patients with cancer? Findings This meta-analysis of 203 studies with more than 6.3 million participants found that obesity was associated with increased overall and cancer-specific mortality, especially among patients with breast, colon, and uterine cancer. In contrast, patients with obesity and renal cell carcinoma, lung cancer, or melanoma had better survival than patients without obesity. Meaning These findings suggest that survival outcomes are poor among patients with obesity and cancer, except in lung cancer and melanoma. INTRODUCTION Obesity, defined as a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) greater than 30, is a chronic disease with increasing prevalence around the world, largely contributing to important health issues in most countries.1 Alongside body fat, which is a general risk factor for serious illness (eg, metabolic syndrome), greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic deposits.2 Several large epidemiologic studies have evaluated the association between obesity and mortality. In particular, a meta-analysis of 230 cohort studies including more than 30 million individuals3 found that both obesity and overweight were associated with an increased risk of all-cause mortality. Despite the evidence that excess mortality increases with increasing BMI, some studies have reached the conclusion that elevated BMI may improve survival in patients with cardiovascular disease, a phenomenon called the obesity paradox.4 Increased BMI is also associated with an increased risk of multiple cancer types.5 In addition, obesity and overweight may increase cancer mortality.6 During last decades, we have observed a more rapid increase in obesity among adult cancer survivors compared with the general population.7 The mechanisms contributing to higher cancer incidence and mortality may include alterations in sex hormone metabolism, insulin and insulin-like growth factor levels, and adipokine pathways.8,9 Various studies have suggested that patients with cancer and a normal BMI (ie, 20-25) have worse outcomes than patients with obesity. This phenomenon (ie, the obesity paradox) in cancer is not well understood and presents controversial explanations.10,11,12 Three different meta-analyses have led to different results, in particular in lung and renal cell carcinomas.13,14,15 In lung cancer, obesity is favorably associated with long-term survival of surgical patients. Moreover, in renal cell carcinoma, an inconsistent association of BMI with cancer-specific survival (CSS) was found. Conversely, breast, ovarian, and colorectal cancer are invariably associated with increased mortality in patients with obesity.16,17,18 The main explanations for these observations include the general poor health status of patients with very low BMI. Additionally, weight loss may be associated with frailty and other risk factors (eg, smoking).11 In cancer, obesity is also associated with increased efficacy of programmed cell death 1 and programmed cell death ligand 1 (PD-1/PD-L1) blockade in both tumor-bearing mice and patients.12 This updated systematic review and meta-analysis was conducted to evaluate the prognosis of patients with cancer who have obesity vs those without obesity. METHODS Search Strategy and Inclusion Criteria We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline19,20 A systematic search was conducted of EMBASE, PubMed, and the Cochrane Library for articles published from database inception until September 30, 2020. The following search terms were used: ((carcinoma or cancer or sarcoma or melanoma or (“Neoplasms”[MESH])) AND (obese OR obesity OR 30 kg/m2 OR “body mass index”) AND (hazard ratio) AND survival AND (multivariate OR cox or multivariable). The reference lists of identified articles were then manually searched to identify potentially relevant omitted citations. Articles that were not published in English were not included. Retrospective and observational studies (ie, cohort, case-control) or prospective trials were selected when they reported the association of obesity, defined as a BMI of at least 30, with the risk of death (ie, overall survival [OS]), CSS, disease-free survival (DFS), or progression-free survival (PFS) in patients with cancer compared with counterparts without obesity (ie, BMI <30). We placed no restrictions on study setting, size, race, or country. Included studies were limited to those reporting hazard ratios (HRs) and their corresponding 95% CIs. Studies were restricted to adult patients with solid tumors. Hematologic malignant neoplasms were excluded. Short-term survival studies (eg, postsurgical mortality) were also excluded. Baseline-only BMI evaluation was considered (eg, BMI captured at cancer diagnosis in early-stage cancers or at metastatic disease in advanced-stage cancers). The most up-to-date versions of full-text publications were included. Study selection was performed in 2 stages. First, titles and abstracts were screened; then, selected full-text articles were included according to the eligibility criteria. If pooled analyses of more than 1 study were evaluated for inclusion, the included articles were manually evaluated for duplicate inclusion compared with the other eligible articles. Screening was performed independently by 10 authors (M.G., G.T., A.G., A. Indini, A.C., O.N., V.R., A. Iaculli, L.D., M.S.), and conflicts were handled by consensus with a senior author (F.P.). Data Collection and Quality Assessment Data were collected independently by using a predesigned spreadsheet (Excel version 2007 [Microsoft Corp]). Collected data items included authors, year of publication, study setting and design, median follow-up, treatments received, outcomes, and type of analysis. The primary outcome was OS; secondary end points were CSS and PFS or DFS. Along with data extraction, 1 author (F.P.) assessed study quality according to a modified Newcastle Ottawa Scale (NOS; range 1-9, with 1-3 indicating low quality, 4-6 indicating moderate quality, and 7-9 indicating high quality).21 Statistical Analysis First, pooled HRs with 95% CIs were estimated using random-effects meta-analysis with the generic inverse-variance method for studies that provided fully adjusted HRs. Inconsistency across studies was measured with the I2 method. Cutoff values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. When I2 was larger than 50%, a random-effects model was primarily used because of the retrospective nature of included studies. To examine heterogeneity, we performed exploratory analyses of predefined subgroups based on type of disease, type of study, duration of follow-up, and race. Additionally, to address potential bias and verify our results, we performed sensitivity analyses using a leave-one-out method and the trim-and-fill method.22 These methods explore whether there are potential dominant studies that may have driven the results. Finally, to investigate the risk of publication bias, we applied the Egger test and visually inspected the funnel plots (ie, the Begg test).23 If the distribution of studies is symmetrical, the meta-analysis most likely does not have problems with publication bias. All statistical tests were 2-sided using a significance level of P < .05. All analyses were carried out using Comprehensive Meta-Analysis software version 3.3.070. RESULTS Our literature search yielded 1892 articles, of which 203 (17%) met the inclusion criteria for our overall systematic review of the association of obesity with cancer outcomes (Figure). Most excluded studies did not use the prespecified cutoff value for obesity (ie, BMI values different from 30 in 437 studies) or used a continuous cutoff for risk of